Chiasma, a biotech developing oral therapies for orphan diseases only treated by injections, raised $102 million by offering 6.4 million shares (100% primary) at $16, above the $13-$15 range. Chiasma sold 1.0 million more shares than originally planned.
At its offer price, Chiasma commands a fully diluted market cap of $450 million. It will list on the NASDAQ under the symbol CHMA. Barclays and Cowen & Company acted as lead managers on the deal.
